{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:28:29Z","timestamp":1778758109148,"version":"3.51.4"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,21]]},"abstract":"<jats:p>\n                    Limited data are available on the effectiveness of ledipasvir\/sofosbuvir (LDV\/SOF) compared with glecaprevir\/pibrentasvir (GLE\/PIB) for the treatment of hepatitis C virus genotype 2 infection. The sustained virologic response at 12 weeks (SVR 12) rate and on-treatment fibrosis index-4 (FIB-4) change in HCV GT-1 and GT-2 patients receiving LDV\/SOF and GLE\/PIB treatments were compared using propensity score matching (PSM). The proportion of treatment-na\u00efve patients in each group was 93.3% and 95.7% (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.313), respectively. The overall SVR 12 rates of LDV\/SOF for 12 weeks and GLE\/PIB for 8 weeks were 99.3% (149\/150) and 100% (232\/232), respectively. We conducted 1:1 PSM to compare changes in the FIB-4 index before and after treatment. There was no significant difference in the on-treatment change of FIB-4 in the LDV\/SOF and GLE\/PIB group (3.0\u2005\u00b1\u20052.7 vs 2.8\u2005\u00b1\u20052.5,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.518; 2.9\u2005\u00b1\u20052.5 vs 2.4\u2005\u00b1\u20053.4,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.159). In addition, no significant difference in delta FIB-4 was shown between the groups in the PSM cohort (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.939). Furthermore, on stratifying by FIB-4 subclassification, no significant differences in on-treatment delta FIB-4 were observed between the groups across the low, intermediate, and high FIB-4 subclassification (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.909, 0.155, and 0.819, respectively). Fixed doses of LDV\/SOF and GLE\/PIB are effective for treating HCV GT-1 and GT-2 infections. There were no significant differences between the 2 regimens in on-treatment FIB-4 changes upon reaching SVR 12.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046079","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:03:06Z","timestamp":1764169386000},"page":"e46079","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Consideration of ledipasvir\/sofosbuvir as an alternative to glecaprevir\/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study"],"prefix":"10.1097","volume":"104","author":[{"given":"Hyun Joon","family":"Park","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hepatology, Kosin University College of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoyoung","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9253-5066","authenticated-orcid":false,"given":"Joonho","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hepatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Il","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hepatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Woo","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hepatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neung Hwa","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hepatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20260514","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/liv.12108","article-title":"A nationwide seroepidemiology of hepatitis C virus infection in South Korea.","volume":"33","author":"Kim","year":"2013","journal-title":"Liver Int"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3350\/cmh.2018.1002","article-title":"Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD\/IDSA and 2016 EASL.","volume":"24","author":"Yeon","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.","volume":"7","author":"Blach","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct\u2010acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens.","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C.","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series.","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J Hepatol"},{"key":"R9-20260514","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases \u2013 Infectious Diseases Society of America Recommendations for testing, managing, and treating hepatitis C virus infection.","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1473-3099(15)00157-7","article-title":"Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.","volume":"15","author":"Kohli","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R11-20260514","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/IJGM.S283910","article-title":"Drug\u2013drug interactions of newly approved direct-acting antiviral agents in patients with hepatitis C.","volume":"14","author":"Gao","year":"2021","journal-title":"Int J Gen Med"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"ofy238","DOI":"10.1093\/ofid\/ofy238","article-title":"Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men.","volume":"5","author":"Palaniswami","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.2147\/DDDT.S172512","article-title":"Glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.","volume":"13","author":"Cotter","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.","volume":"67","author":"Chung","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-017-0817-y","article-title":"Glecaprevir\/pibrentasvir: first global approval.","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(15)00529-0","article-title":"Ledipasvir\u2013sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.","volume":"16","author":"Abergel","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R18-20260514","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.","volume":"64","author":"Abergel","year":"2016","journal-title":"Hepatology"},{"key":"R19-20260514","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","article-title":"Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.","volume":"149","author":"Gane","year":"2015","journal-title":"Gastroenterology"},{"key":"R20-20260514","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40265-018-0864-z","article-title":"Ledipasvir\/sofosbuvir: a review in chronic hepatitis C.","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"R21-20260514","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir.","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"R22-20260514","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1053\/j.gastro.2017.01.017","article-title":"Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection.","volume":"152","author":"Gane","year":"2017","journal-title":"Gastroenterology"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/liv.13685","article-title":"Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.","volume":"38","author":"Asahina","year":"2018","journal-title":"Liver Int"},{"key":"R24-20260514","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/hepr.13437","article-title":"Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: a propensity score matched analysis.","volume":"50","author":"Ogawa","year":"2020","journal-title":"Hepatol Res"},{"key":"R25-20260514","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy.","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"R26-20260514","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/jgh.13473","article-title":"Impact of FIB\u20104 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: an analysis using time-dependent receiver operating characteristic.","volume":"32","author":"Tada","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"R27-20260514","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection.","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"R28-20260514","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"R29-20260514","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.14309\/ajg.0000000000001281","article-title":"Ledipasvir\/sofosbuvir for 8, 12, or 24 weeks in hepatitis C patients undergoing dialysis for end-stage renal disease.","volume":"116","author":"Chuang","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R30-20260514","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12072-018-9859-9","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.","volume":"12","author":"Okubo","year":"2018","journal-title":"Hepatol Int"},{"key":"R31-20260514","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.30830","article-title":"Ledipasvir\u2013sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C.","volume":"71","author":"Schwarz","year":"2020","journal-title":"Hepatology"},{"key":"R32-20260514","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.anpedi.2018.07.007","article-title":"Combinaci\u00f3n de ledipasvir\/sofosbuvir como tratamiento de la infecci\u00f3n cr\u00f3nica por hepatitis C.","volume":"90","author":"Quintero","year":"2019","journal-title":"An Pediatr"},{"key":"R33-20260514","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/hep.30123","article-title":"Safety and efficacy of ledipasvir\u2013sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6\u201311.","volume":"68","author":"Murray","year":"2018","journal-title":"Hepatology"},{"key":"R34-20260514","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/hepr.13546","article-title":"Twelve weeks of ledipasvir\/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: integrated analysis of three clinical trials.","volume":"50","author":"Asahina","year":"2020","journal-title":"Hepatol Res"},{"key":"R35-20260514","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3904\/kjim.2022.013","article-title":"Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.","volume":"37","author":"Lee","year":"2022","journal-title":"Korean J Intern Med"},{"key":"R36-20260514","doi-asserted-by":"crossref","first-page":"13651","DOI":"10.1038\/s41598-018-31839-y","article-title":"Differential effect of HCV eradication and fibrosis grade on hepatocellular carcinoma and all-cause mortality.","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"key":"R37-20260514","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13337-020-00592-0","article-title":"HCV genotypes and their determinative role in hepatitis C treatment.","volume":"31","author":"Keikha","year":"2020","journal-title":"VirusDisease"},{"key":"R38-20260514","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome.","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J Hepatol"},{"key":"R39-20260514","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2019.03.011","article-title":"Rwanda launches a 5-year national hepatitis C elimination plan: a landmark in sub-Saharan Africa.","volume":"70","author":"Umutesi","year":"2019","journal-title":"J Hepatol"},{"key":"R40-20260514","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40262-018-0654-5","article-title":"Drug\u2013drug interaction profile of the fixed-dose combination tablet regimen ledipasvir\/sofosbuvir.","volume":"57","author":"German","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R41-20260514","doi-asserted-by":"crossref","first-page":"e19140","DOI":"10.1097\/MD.0000000000019140","article-title":"Hepatitis C virus treatment response to ledipasvir\/sofosbuvir among patients coinfected with HIV and HCV: real world data in a black population.","volume":"99","author":"Banga","year":"2020","journal-title":"Medicine (Baltim)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:06:28Z","timestamp":1778756788000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":40,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046079","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2024-08-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}